FDA Approves Indication for Pemfexy in Combination with Pembrolizumab and Platinum Chemotherapy
Eagle Pharmaceuticals, Inc announced today that the U.S. Food and Drug
Administration has approved an additional indication for Pemfexy® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations. Eagle’s approved Pemfexy (pemetrexed injection) is a ready-to-dilute (“RTD”) novel liquid intravenous formulation developed to eliminate the reconstitution step of the Listed Drug (“LD”), ALIMTA®.
